MicroRNA‑217 inhibits the proliferation and invasion, and promotes apoptosis of non‑small cell lung cancer cells by targeting sirtuin 1

Li,Guangshun; Zhong,Shouping

doi:10.3892/ol.2021.12647

MicroRNA‑217 inhibits the proliferation and invasion, and promotes apoptosis of non‑small cell lung cancer cells by targeting sirtuin 1

Authors:
- Guangshun Li
- Shouping Zhong
View Affiliations

Affiliations: Department of Thoracic, Xi'an Central Hospital, Xi'an, Shaanxi 710003, P.R. China
Published online on: March 17, 2021 https://doi.org/10.3892/ol.2021.12647
Article Number: 386
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is a common malignancy worldwide. MicroRNA (miR)‑217 and sirtuin 1 (SIRT1) have been reported to play significant roles in different types of cancer, such as osteosarcoma and prostate cancer; however, the association between miR‑217 and SIRT1 in the cell proliferation, apoptosis and invasion of NSCLC remain unknown. Thus, the present study aimed to investigate the roles of miR‑217 and SIRT1 in NSCLC. The expression levels of miR‑217 and SIRT1 were detected via reverse transcription‑quantitative (RT‑q)PCR and western blot analyses. The effect of miR‑217 on A549 and H1299 cell proliferation, apoptosis and invasion was assessed via the Cell Counting Kit‑8, flow cytometry and Transwell assays, respectively. In addition, the association between SIRT1 and miR‑217 was predicted using the TargetScan database, and verified via the dual‑luciferase reporter assay, and RT‑qPCR and western blot analyses. The results demonstrated that miR‑217 expression was significantly downregulated, while SIRT1 expression was significantly upregulated in A549 and H1299 cells compared with the human bronchial epithelial cells. Furthermore, transfection with miR‑217 mimic significantly inhibited A549 and H1299 cell proliferation and invasion, and induced A549 and H1299 cell apoptosis. The results of the dual‑luciferase reporter assay and western blot analysis confirmed that SIRT1 is a target gene of miR‑217. In addition, miR‑217 inhibited the activation of AMP‑activated protein kinase (AMPK) and mTOR signaling. Taken together, the results of the present study suggest that miR‑217 inhibits A549 and H1299 cell proliferation and invasion, and induces A549 and H1299 cell apoptosis by targeting SIRT1 and inactivating the SIRT1‑mediated AMPK/mTOR signaling pathway. Thus, miR‑217 may be used as a potential therapeutic target for the treatment of patients with NSCLC.

View Figures

View References

1	Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, et al: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of nonsmall cell lung cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI
2	Zhang L, Shi SB, Zhu Y, Qian TT and Wang HL: Long non-coding RNA ASAP1-IT1 promotes cell proliferation, invasion and metastasis through the PTEN/AKT signaling axis in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 22:142–149. 2018.PubMed/NCBI
3	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
4	NSCLC Meta-analyses Collaborative Group and Arriagada R, ; Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, Le Pechoux C, Parmar MK, Pignon JP, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet. 375:1267–1277. 2010. View Article : Google Scholar : PubMed/NCBI
5	Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in China, 2003–2005: A population-based study. Int J Cancer. 136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
6	Wu S, Zhao X, Wu S, Du R, Zhu Q, Fang H, Zhang X, Zhang C, Zheng W, Yang J and Feng H: Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer. Oncotarget. 7:81750–81756. 2016. View Article : Google Scholar : PubMed/NCBI
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu T, Wu X, Chen T, Luo Z and Hu X: Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/β-catenin signaling. Clin Cancer Res. 24:1748–1760. 2018. View Article : Google Scholar : PubMed/NCBI
9	Paliouras AR, Monteverde T and Garofalo M: Oncogene-induced regulation of microRNA expression: Implications for cancer initiation, progression and therapy. Cancer Lett. 421:152–160. 2018. View Article : Google Scholar : PubMed/NCBI
10	Guo J, Feng Z, Huang Z, Wang H and Lu W: MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer. Mol Cells. 37:664–671. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lu L, Luo F, Liu Y, Liu X, Shi L, Lu X and Liu Q: Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract. Toxicol Appl Pharmacol. 289:276–285. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z, Wang J, Lu Y, Yu Q, Su H, et al: Histone deacetylase SIRT1 negatively regulates the differentiation ofinterleukin-9-producing CD4⁺ T cells. Immunity. 44:1337–1349. 2016. View Article : Google Scholar : PubMed/NCBI
13	Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin AM, Larráyoz M, Idoate MA, Gall-Troselj K, Pio R and Montuenga LM: Pression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 10:e01246702015. View Article : Google Scholar : PubMed/NCBI
14	Han L, Liang XH, Chen LX, Bao SM and Yan ZQ: SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration. Int J Clin Exp Pathol. 6:2357–2365. 2013.PubMed/NCBI
15	He S, Wang Z, Tang H, Dong J, Qu Y and Lv J: miR-217 inhibits proliferation, migration, and invasion by targeting SIRT1 in osteosarcoma. Cancer Biother Radiopharm. 34:264–270. 2019. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zhu L, Yang S and Wang J: miR-217 inhibits the migration and invasion of HeLa cells through modulating MAPK1. Int J Mol Med. 44:1824–1832. 2019.PubMed/NCBI
18	Jiang B, Zhu SJ, Xiao SS and Xue M: miR-217 inhibits M2-Like macrophage polarization by suppressing secretion of interleukin-6 in ovarian cancer. Inflammation. 42:1517–1529. 2019. View Article : Google Scholar : PubMed/NCBI
19	Yang CL, Zheng XL, Ye K and Xue M: Effects of microRNA-217 on proliferation, apoptosis, and autophagy of hepatocytes in rat models of CCL4-induced liver injury by targeting NAT2. J Cell Physiol. 234:3410–3424. 2019. View Article : Google Scholar : PubMed/NCBI
20	Liu C, Zhang Z and Qi D: Circular RNA hsa_circ_0023404 promotes proliferation, migration and invasion in non-small cell lung cancer by regulating miR-217/ZEB1 axis. Onco Targets Ther. 12:6181–6189. 2019. View Article : Google Scholar : PubMed/NCBI
21	Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
22	Wong S and Weber JD: Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem J. 407:451–460. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD and Chen J: Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 8:1025–1031. 2006. View Article : Google Scholar : PubMed/NCBI
24	Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
25	Alves-Fernandes DK and Jasiulionis MG: The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 20:31532019. View Article : Google Scholar
26	Jiang W, Hou L, Wei J, Du Y, Zhao Y, Deng X and Lin X: Hsa-miR-217 inhibits the proliferation, migration, and invasion in non-small cell lung cancer cells via targeting SIRT1 and P53/KAI1 signaling. Balkan Med J. 37:208–214. 2020.PubMed/NCBI
27	Zhang L, Chen J, He Q, Chao Z, Li X and Chen M: MicroRNA-217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1. Mol Med Rep. 20:3182–3190. 2019.PubMed/NCBI
28	Xia K, Zhang Y and Sun D: miR-217 and miR-543 downregulation mitigates inflammatory response and myocardial injury in children with viral myocarditis by regulating the SIRT1/AMPK/NF-κB signaling pathway. Int J Mol Med. 45:634–646. 2020.PubMed/NCBI
29	Salomone F, Barbagallo I, Godos J, Lembo V, Currenti W, Cinà D, Avola R, D'Orazio N, Morisco F, Galvano F and Li Volti G: Silibinin restores NAD(+) levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver. Nutrients. 9:102017. View Article : Google Scholar
30	Patra KC, Weerasekara VK and Bardeesy N: AMPK-mediated lysosome biogenesis in lung cancer growth. Cell Metab. 29:238–240. 2019. View Article : Google Scholar : PubMed/NCBI
31	Li C, Dong Y, Wang L, Xu G, Yang Q, Tang X, Qiao Y and Cong Z: Ginsenoside metabolite compound K induces apoptosis and autophagy in non-small cell lung cancer cells via AMPK-mTOR and JNK pathways. Biochem Cell Biol. 97:406–414. 2019. View Article : Google Scholar : PubMed/NCBI
32	He K, Guo X, Liu Y, Li J, Hu Y, Wang D and Song J: TUFM downregulation induces epithelial-mesenchymal transition and invasion in lung cancer cells via a mechanism involving AMPK-GSK3β signaling. Cell Mol Life Sci. 73:2105–2121. 2016. View Article : Google Scholar : PubMed/NCBI
33	Yan G, Ru Y, Wu K, Yan F, Wang Q, Wang J, Pan T, Zhang M, Han H, Li X and Zou L: GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. Prostate. 78:166–177. 2017. View Article : Google Scholar : PubMed/NCBI
34	Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, Buchan JR and Cho WC: Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 18:3672017. View Article : Google Scholar
35	Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J, Li Z, Chen B, Zhang X, Pan H, et al: MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer Res. 77:5782–5794. 2017. View Article : Google Scholar : PubMed/NCBI
36	Zhao W, Peng F, Shu M, Liu H, Hou X, Wang X, Ye J, Zhao B, Wang K, Zhong C, et al: Isogambogenic acid inhibits the growth of glioma through activation of the AMPK-mTOR pathway. Cell Physiol Biochem. 44:1381–1395. 2017. View Article : Google Scholar : PubMed/NCBI
37	Dong LX, Sun LL, Zhang X, Pan L, Lian LJ, Chen Z and Zhong DS: Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells. Acta Pharmacol Sin. 34:314–318. 2013. View Article : Google Scholar : PubMed/NCBI